Oncology drug discovery: Planning a turnaround

32Citations
Citations of this article
62Readers
Mendeley users who have this article in their library.

Abstract

We have made remarkable progress in our understanding of the pathophysiology of cancer. This improved understanding has resulted in increasingly effective targeted therapies that are better tolerated than conventional cytotoxic agents and even curative in some patients. Unfortunately, the success rate of drug approval has been limited, and therapeutic improvements have been marginal, with too few exceptions. In this article, we review the current approach to oncology drug discovery and development, identify areas in need of improvement, and propose strategies to improve patient outcomes. We also suggest future directions that may improve the quality of preclinical and early clinical drug evaluation, which could lead to higher approval rates of anticancer drugs. © 2014 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Toniatti, C., Jones, P., Graham, H., Pagliara, B., & Draetta, G. (2014). Oncology drug discovery: Planning a turnaround. Cancer Discovery, 4(4), 397–404. https://doi.org/10.1158/2159-8290.CD-13-0452

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free